Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Merck & Co., Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Merck & Co., Inc.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Merck & Co., Inc.
  • The firm trades with high earnings multiples: 50.13 times its 2026 earnings per share.
  • The company's enterprise value to sales, at 4.67 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Rating Financials

Merck & Co., Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Merck & Co., Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Merck & Co., Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Merck & Co., Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Merck & Co., Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
278B
A
883B
A
540B
BBB
367B -
AA
- -
328B
AA
288B
A
283B
AAA
206B
A
181B
A
168B
AA
Average 352.13B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Ratings Merck & Co., Inc.